Healthtech startup Langaware, based in Greece, receives €2 million in seed funding. Eleven Ventures led the company’s Seed round, and Metavallon VC also took part.As it grows its market share in the US, the company plans to use the financing to further build its product and technical teams.
Langaware uses artificial intelligence (AI) to evaluate language, voice, and speech using digital biomarkers in order to anticipate and monitor illnesses like mild cognitive decline, Alzheimer’s disease, and depression. In the end, early diagnosis helps the pharmaceutical industry, health systems, and clinicians deliver appropriate, individualized treatment for patients and assistance.
The Langaware platform, the result of years of study, has been tested and proven successful in both clinical and virtual care environments in the US and Greece.
Langaware founder and CEO Vassiliki Rentoumi said: “This investment propels us forward, unlocking the potential to revolutionise healthcare systems by unleashing the full power of AI. By harnessing the power of technology, we aim to alleviate the strain on overburdened healthcare systems, while driving down costs and fostering a future where accessible, high-quality healthcare is a fundamental right for all.”
Their goal is to bring to an era when mental health and cognitive problems are identified in their infancy, resulting in more efficient treatments, less financial strain on the medical system, and more overall wellbeing.
In their ideal future, AI-driven diagnostic tools are seamlessly integrated into healthcare delivery systems, providing medical professionals with insightful data and facilitating individualized care.
They work to change the face of cognitive and mental healthcare, enhancing access, results, and quality of life for everyone by encouraging early intervention and de-stigmatizing mental illness.